Pembrolizumab

Introduction Overview

Generic Name

pembrolizumab

Brand Name

Keytruda

Dosage Form

single-dose vial for intravenous infusion (100 mg/4 mL)

Drug Class

Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Pharmacokinetics

Absorption: As an intravenous immunotherapy agent, pembrolizumab (Keytruda) bypasses the gastrointestinal tract and is directly introduced into systemic circulation via slow intravenous infusion over approximately 30 minutes. This route eliminates concerns of traditional oral absorption variability. Distribution: Once infused, pembrolizumab distributes mainly into the extracellular fluid compartment. Due to its nature as a large monoclonal antibody (IgG4 subtype), it exhibits limited distribution into tissues compared to small molecule drugs but can penetrate tumor microenvironments. It does not easily cross the blood-brain barrier. The volume of distribution approximates plasma volume, consistent with monoclonal antibodies. Metabolism: Pembrolizumab is predominantly catabolized through nonspecific proteolytic degradation pathways into small peptides and amino acids. This process occurs ubiquitously throughout the reticuloendothelial system without involvement of cytochrome P450 enzymes, minimizing drug-drug interaction potential. Elimination: The elimination half-life of pembrolizumab is approximately 22 days (range: 13 to 27 days), consistent with IgG4 antibodies. Clearance occurs primarily through proteolytic catabolism rather than renal or hepatic clearance. There is no dose adjustment required for renal or hepatic impairment. Steady-state concentrations are typically achieved by 16 weeks of repeated dosing. Clinical implications include a dosing interval of every 3 to 6 weeks depending on the treatment regimen and cancer type.

Dosage Forms

Available Dosage Forms: Keytruda is provided as a single-dose vial intended for intravenous infusion. The vial strength is 100 mg of pembrolizumab in 4 mL (25 mg/mL). Previously, a 50 mg vial was available but has been discontinued. Dosages for Adults and Adolescents: The typical adult dosing regimen varies based on cancer type and indication but commonly includes 200 mg every 3 weeks or 400 mg every 6 weeks for certain indications such as classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. In melanoma and some other indications, dosing every 3 weeks is standard. Adolescents aged 12 years and older can be dosed similarly to adults for approved indications such as resected melanoma. Specific Patient Populations: Pediatric dosing (for children under 12 years) depends on body weight, with dosing regimens adjusted accordingly, and is approved for selected indications including classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. There is currently no generic or biosimilar alternative available. Patients with impaired hepatic or renal function do not require dose adjustments due to pembrolizumab's catabolic elimination pathway. Dosing schedules and cycles may be modified based on tolerability and clinical response, guided by oncologist discretion and clinical trial protocols.

Mechanism Of Action

Pembrolizumab (Keytruda) is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor found on the surface of activated T cells. Under normal conditions, PD-1 engagement by its ligands PD-L1 and PD-L2 functions as an immune checkpoint that downregulates T-cell activity to maintain immune homeostasis and prevent autoimmunity. Many tumors exploit this mechanism by overexpressing PD-L1/PD-L2, effectively engaging PD-1 and inducing T cell anergy, exhaustion, or apoptosis, thus evading immune surveillance. Pembrolizumab binds with high affinity and specificity to the PD-1 receptor, blocking its interaction with the ligands PD-L1 and PD-L2. This blockade removes inhibitory signaling, effectively releasing the immune checkpoint 'brake' on cytotoxic T lymphocytes (CTLs). As a result, T cells regain their ability to recognize, proliferate, and destroy tumor cells expressing neoantigens. The drug enhances endogenous anti-tumor immunity by restoring and amplifying T-cell mediated immune responses against various malignancies. Compared to similar drugs like nivolumab, which also target PD-1, pembrolizumab has subtle differences in dosing intervals and some clinical efficacy differences for specific cancers, but shares the core immune checkpoint inhibitory mechanism. Extensive clinical trials demonstrate pembrolizumab efficacy across a wide range of tumors, including melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, and others with molecular biomarkers predicting response such as PD-L1 expression, microsatellite instability-high status, and tumor mutational burden. Thus, pembrolizumab embodies a precision immunotherapy approach leveraging immune modulation and tumor immunobiology.

Pharmacological Actions

Immune checkpoint inhibition by blocking PD-1 receptor on T cells.
Restoration and enhancement of T-cell mediated anti-tumor immune response.
Prevention of tumor immune evasion mediated by PD-L1/PD-L2 expression.
Monoclonal antibody targeting specifically the PD-1 receptor (IgG4 subtype).
Modulation of tumor microenvironment to facilitate immune cell infiltration and cytotoxicity.
Synergistic potential when combined with chemotherapy, radiotherapy, or other immunotherapies.
Induction of durable tumor regression and prolonged survival in various cancers.
Non-chemotherapeutic immunomodulatory mechanism resulting in a different toxicity profile compared to cytotoxic agents.
Ability to treat multiple tumor types with common immune checkpoint biology.
Inhibits negative immune regulatory pathways that limit immune responses.
Supports immunologic memory formation against tumor antigens.
Potential to overcome resistance associated with prior therapies through immune activation.
May produce immune-related adverse events due to systemic immune activation.
Long half-life supporting infrequent dosing intervals.
Catabolized by proteolytic pathways without cytochrome P450 involvement.

Therapeutic Or Clinical Uses

Treatment of unresectable or metastatic melanoma.
Adjuvant treatment of completely resected Stage IIB, IIC, or III melanoma.
First-line and subsequent-line therapy for metastatic non-small cell lung cancer (NSCLC) based on PD-L1 expression and genetic mutation status.
Treatment of unresectable advanced or metastatic malignant pleural mesothelioma in combination with chemotherapy.
Management of resectable and unresectable head and neck squamous cell carcinoma (HNSCC).
Relapsed or refractory classical Hodgkin lymphoma (adults and children).
Treatment of refractory primary mediastinal large B-cell lymphoma (PMBCL).
Therapy for locally advanced or metastatic urothelial carcinoma, including BCG-unresponsive non-muscle invasive bladder cancer.
Management of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors and colorectal cancers.
First-line and later-line treatment of gastric and esophageal cancers with PD-L1 expression.
Therapy for locally advanced cervical cancer and persistent, recurrent, or metastatic cervical cancer with PD-L1 expression.
Management of hepatocellular carcinoma post prior systemic therapy.
Treatment of biliary tract cancers in combination with chemotherapy.
Recurrent Merkel cell carcinoma treatment.
First-line and adjuvant treatment for advanced and high-risk renal cell carcinoma.
Management of advanced or recurrent endometrial carcinoma with combination or single-agent therapy based on molecular markers.
Treatment of tumor mutational burden-high (TMB-H) solid tumors post prior therapy.
Therapy of cutaneous squamous cell carcinoma not amenable to surgery or radiation.
Treatment of triple-negative breast cancer (TNBC), including neoadjuvant and metastatic settings with PD-L1 expression.

Side Or Adverse Effects

Fatigue or excessive tiredness is common both alone and in combination therapy.
Pain including stomach, muscle, bone, or joint pain.
Rash, itching, and various dermatologic reactions including blistering, peeling, and rash on palms and soles.
Gastrointestinal disturbances including diarrhea, constipation, nausea, vomiting, and abdominal pain.
Fever and flu-like symptoms.
Cough, shortness of breath, and other respiratory symptoms.
Decreased appetite and weight loss.
Low levels of thyroid hormone (hypothyroidism) and other endocrine abnormalities including adrenal insufficiency and diabetes mellitus.
Nervous system side effects such as headache, neuropathy, weakness, paralysis, and in rare cases, immune-mediated neuropathies.
Inflammation of organs due to immune-related adverse effects including pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies.
Infusion reactions including chills, fever, flushing, dizziness, rash, and respiratory distress.
Swelling and inflammation of mucous membranes including mouth sores and mucositis.
Bleeding and bruising due to hematologic effects.
Low blood cell counts including anemia, leukopenia, and thrombocytopenia.
Rare but serious immune-mediated adverse events affecting multiple organ systems that can be life-threatening if untreated.
Possible increased blood pressure during treatment.

Precautions

Careful monitoring advised in patients with pre-existing autoimmune disorders such as rheumatoid arthritis, lupus, Crohn's disease, ulcerative colitis, or psoriasis.
Baseline and periodic assessment for immune-related adverse effects required including liver, kidney, and thyroid function tests.
Close observation and management recommended for patients receiving or planned for allogeneic stem cell or organ transplantation due to risk of graft rejection or graft-versus-host disease.
Avoid use in patients with active systemic infections without appropriate treatment.
Use contraception during treatment and for at least four months after last dose to prevent fetal harm.
Discontinue breastfeeding during and for at least four months following therapy due to potential drug excretion into breast milk and unknown effects.
Evaluate patients for prior chest radiation history due to higher risk of pneumonitis.
Cautious use in patients with pre-existing neurologic disorders such as myasthenia gravis or Guillain-Barré syndrome due to potential exacerbation.
Patients should be educated about early signs and symptoms of immune-related adverse events for prompt reporting.
Avoid concurrent immunosuppressive therapy unless medically indicated to treat immune-mediated toxicities.
Monitor for infusion-related reactions during and after administration.
Regular clinical and laboratory follow-up is essential to detect delayed immune adverse events.
Individualize dosing intervals and treatment duration based on therapeutic response and toxicity.
Inform patients about potential need for corticosteroids or other immunosuppressants to manage adverse effects.
Consider special populations such as pediatric patients where approved indications exist and dosing adjustments are specified.

Warnings

Severe and potentially fatal immune-related adverse events can occur affecting lungs (pneumonitis), intestines (colitis), liver (hepatitis), endocrine glands, kidneys, skin, and other organs.
Immune-mediated reactions can occur at any time during treatment or even after discontinuation.
Prompt recognition and treatment of immune-related adverse effects are critical to reduce morbidity and mortality.
Infusion reactions may be severe or life-threatening; emergency measures must be available during administration.
Use with caution in patients with previous organ transplants due to risk of graft rejection.
May cause fetal harm; contraindicated in pregnancy unless benefit outweighs risk.
Potential for graft-versus-host disease in patients undergoing allogeneic bone marrow transplantation before or after treatment.
Risk of severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Monitoring required for adrenal insufficiency and other hormone gland dysfunctions that can be life-threatening if untreated.
Patients should be monitored for signs of infection during treatment due to immune modulation.
Discontinue therapy for severe or life-threatening adverse reactions; may require high-dose corticosteroid therapy.
Potential for multi-organ failure with unchecked immune activation.
Patients should carry information regarding immunotherapy treatment and advise healthcare providers accordingly.
Risk of severe allergic reactions including anaphylaxis during infusion.
Continuous post-treatment follow-up is needed since adverse events can arise after therapy cessation.

Contraindication

Known hypersensitivity to pembrolizumab or any component of the formulation such as L-histidine, polysorbate 80, sucrose, or water for injection.
Pregnant women unless no alternative treatment is available and potential benefit justifies risk to the fetus.
Patients with active severe autoimmune diseases where the risks of immune activation outweigh benefits unless condition is well controlled or benefit is substantial.
Concomitant use in patients who require systemic immunosuppression that could impair pembrolizumab efficacy.
Patients with history of severe infusion reactions to pembrolizumab not manageable with premedication.
Use in patients who have received allogeneic stem cell transplantation with uncontrolled graft-versus-host disease.
Known contraindications to intravenous infusion administration such as severe injection site infection or compromised venous access preventing safe administration.

Drug Interactions

Minimal direct pharmacokinetic interactions due to monoclonal antibody catabolism via proteolysis rather than cytochrome P450 metabolism.
Potential interaction with immunosuppressive agents such as corticosteroids which may diminish the immunotherapeutic effect of pembrolizumab.
Concurrent chemotherapy may increase risk of immunosuppression and additive toxicities; requires monitoring.
Co-administration with other immune checkpoint inhibitors (e.g., nivolumab) may increase frequency and severity of immune-related adverse events.
Drugs that modulate immune system function can potentially affect pembrolizumab efficacy and toxicity profile.
Use caution with vaccines: live vaccines are generally contraindicated during and after treatment until immune recovery.
Concomitant use of warfarin or other anticoagulants requires monitoring due to bleeding risk from immune-related thrombocytopenia.
Potential additive risk of pneumonitis with drugs that affect lung function.
Agents causing nephrotoxicity may compound potential renal adverse effects of pembrolizumab.
Co-administration with agents causing hepatotoxicity requires liver function monitoring due to risk of immune-mediated hepatitis.
Caution with drugs affecting thyroid function or replacement therapies due to risk of hypothyroidism or hyperthyroidism induced by immunotherapy.
Limited data on interactions with herbal supplements; patients should disclose use of all supplements.
No known interaction with commonly used analgesics or antiemetics, but clinical monitoring advised.
Monitoring recommended when pembrolizumab is combined with novel therapies given evolving evidence.
Patients should inform healthcare providers about all medications, including over-the-counter and vitamins, due to possible indirect effects.

Preparations Of The Drug

Single-dose vial formulation containing 100 mg pembrolizumab in 4 mL sterile aqueous solution (25 mg/mL).
Inactive ingredients include L-histidine (buffering agent), polysorbate 80 (surfactant), sucrose (stabilizer), and water for injection (solvent).
Supplied as a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for intravenous infusion.
Vials are intended for single use only; unused portions must be discarded to prevent contamination.
Prepared under aseptic conditions and diluted in appropriate intravenous fluids (e.g., 0.9% sodium chloride) for infusion.
Storage requires refrigeration at 2-8°C and protection from light; do not freeze.
Dosing is determined by oncologist and tailored to indication, weight, and clinical status.
Manufactured by Merck & Co. (MSD outside USA and Canada) under rigorous quality control standards.
No approved generic or biosimilar products currently available; one discontinued 50 mg vial formulation existed previously.
Administration involves slow intravenous infusion over 30 minutes with proper infusion devices and filters per prescribing guidelines.
Prepared doses must be used promptly or refrigerated for limited periods per manufacturer instructions to maintain stability.
Instructions for dilution and infusion preparation available in prescribing information to ensure correct handling and administration.
Should be handled by qualified healthcare professionals trained in immunotherapy infusion protocols.
Monitoring during and after infusion is standard practice to manage potential infusion reactions.
Disposal of unused drug and materials should comply with local regulations for biological and hazardous waste.